Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
571
datasets available to search
ShareScore release 0.9.0
Dataset results
571 results for “CLL”
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
ClinicalTrials.gov study NCT04515238. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
ClinicalTrials.gov study NCT00772486. IPD Sharing: Not stated. Countries: 1. Publications: 23.
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00628238. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00103558. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
ClinicalTrials.gov study NCT05254743. IPD Sharing: YES. Countries: 23. Publications: 0.
Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine
ClinicalTrials.gov study NCT01392079. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT03986034. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
ClinicalTrials.gov study NCT00349349. IPD Sharing: Not stated. Countries: 0. Publications: 3.
Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)
ClinicalTrials.gov study NCT00147901. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00046488. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
ClinicalTrials.gov study NCT00603668. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
ClinicalTrials.gov study NCT04883749. IPD Sharing: NO. Countries: 2. Publications: 1.
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT03479268. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT02500407. IPD Sharing: YES. Countries: 7. Publications: 15.
Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
ClinicalTrials.gov study NCT02445131. IPD Sharing: NO. Countries: 1. Publications: 1.
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
ClinicalTrials.gov study NCT01853631. IPD Sharing: NO. Countries: 1. Publications: 1.
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT02200848. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
ClinicalTrials.gov study NCT01039376. IPD Sharing: YES. Countries: 25. Publications: 0.
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
ClinicalTrials.gov study NCT04639362. IPD Sharing: NO. Countries: 2. Publications: 1.
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00289549. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.